Xience Prime time
This article was originally published in The Gray Sheet
Executive Summary
Abbott receives CE mark approval for the next-generation everolimus-eluting coronary stent, clearing the way for a European market launch in the third quarter, the firm says June 23. Xience Prime uses the same drug and biocompatible polymer as Abbott's market-leading Xience V stent, available in the U.S. and Europe, but has a novel design and modified delivery system for greater flexibility and improved deliverability, the company says (1"The Gray Sheet" July 7, 2008). Xience Prime will be available in a broad range of sizes, including Prime SV for small vessels and Prime LL for long lesions